Vistagen (VTGN) Chief Corp Dev Officer Elissa Cote Receives 75,000 Options

What Happened Elissa S. Cote, Chief Corporate Development Officer of Vistagen Therapeutics (VTGN), received a grant of 75,000 stock options (reported as a derivative award) on April 7, 2026. The Form 4 lists the acquisition as 75,000 units at $0.00 because it records an option grant rather than an open-market stock purchase; the filing excerpt does not specify an exercise price or immediate cash value.

Key Details

• Transaction date: April 7, 2026; Form 4 filed April 9, 2026 (appears timely within the two-business-day reporting window).
• Reported transaction: Grant/award of 75,000 options (derivative); acquisition price shown as $0.00 on the Form 4.
• Vesting (per footnote): 25% vests six months after April 7, 2026 (Oct 7, 2026) and then in 25% installments every six months, fully vesting on April 7, 2028.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax-withholding sale, or other special conditions in the excerpt.

Context This is a standard equity compensation award to an executive, not an open-market purchase or sale. Option grants are common as retention/incentive compensation and do not represent immediately tradable shares until vested and exercised. The filing does not state the option exercise price or whether any options were exercised or sold.